https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:6943 Wed 11 Apr 2018 18:38:10 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4569 Wed 11 Apr 2018 16:57:52 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:6937 Wed 11 Apr 2018 15:48:16 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8456 Wed 11 Apr 2018 13:48:59 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28081 Wed 11 Apr 2018 13:03:57 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:562 Wed 11 Apr 2018 12:44:12 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4458 Wed 11 Apr 2018 12:44:10 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1439 Wed 11 Apr 2018 11:51:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:2834 Wed 11 Apr 2018 11:47:59 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14333 2.7 million exposed individuals. Of the extensively studied drugs (ten or more studies), the highest overall risks were seen with rofecoxib, 1.45 (95% CI 1.33, 1.59), and diclofenac, 1.40 (1.27, 1.55), and the lowest with ibuprofen, 1.18 (1.11, 1.25), and naproxen, 1.09 (1.02, 1.16). In a sub-set of studies, risk was elevated with low doses of rofecoxib, 1.37 (1.20, 1.57), celecoxib, 1.26 (1.09, 1.47), and diclofenac, 1.22 (1.12, 1.33), and rose in each case with higher doses. Ibuprofen risk was seen only with higher doses. Naproxen was risk-neutral at all doses. Of the less studied drugs etoricoxib, 2.05 (1.45, 2.88), etodolac, 1.55 (1.28, 1.87), and indomethacin, 1.30 (1.19, 1.41), had the highest risks. In pair-wise comparisons, etoricoxib had a higher RR than ibuprofen, RRR = 1.68 (99% CI 1.14, 2.49), and naproxen, RRR = 1.75 (1.16, 2.64); etodolac was not significantly different from naproxen and ibuprofen. Naproxen had a significantly lower risk than ibuprofen, RRR = 0.92 (0.87, 0.99). RR estimates were constant with different background risks for cardiovascular disease and rose early in the course of treatment. Conclusions: This review suggests that among widely used NSAIDs, naproxen and low-dose ibuprofen are least likely to increase cardiovascular risk. Diclofenac in doses available without prescription elevates risk. The data for etoricoxib were sparse, but in pair-wise comparisons this drug had a significantly higher RR than naproxen or ibuprofen. Indomethacin is an older, rather toxic drug, and the evidence on cardiovascular risk casts doubt on its continued clinical use.]]> Wed 11 Apr 2018 11:27:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:471 Thu 25 Jul 2013 09:09:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:164 Thu 25 Jul 2013 09:09:46 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8258 Thu 13 Jun 2019 16:58:27 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9394 Sat 24 Mar 2018 08:39:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7014 Sat 24 Mar 2018 08:38:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9648 60 years is growing faster than any other age group and is expected to reach 2 billion worldwide by 2050. Internationally and nationally, considerable efforts are being made to promote active ageing. However, Australia lacks the kind of comprehensive longitudinal research underway in Europe and North America. Although Australia does have a number of longitudinal studies designed to address various issues of health and ageing among older adults, only a few of these studies include a broad and comprehensive range of physical and biological measures. The Hunter Community Study (HCS) is a collaborative study between the University of Newcastle’s School of Medicine and Public Health and the Hunter New England Area Health Service. It is a multi disciplinary initiative that was established to fill some existing gaps in ageing research in Australia and is unique in that it has collected detailed information across all six key policy themes as identified in the Framework for an Australian Ageing Research Agenda.]]> Sat 24 Mar 2018 08:35:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1296 Sat 24 Mar 2018 08:32:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1289 Sat 24 Mar 2018 08:32:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:2835 Sat 24 Mar 2018 08:29:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1438 Sat 24 Mar 2018 08:28:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1750 Sat 24 Mar 2018 08:27:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:2260 US $382; odds ratio [OR], 3.5; 95% confidence interval [CI], 2.6-4.7) and support for attending international conferences (OR, 5.4; 95% CI, 3.9-7.4). The strongest associations were seen for acting as a paid consultant to industry (OR, 9.0; 95% CI, 3.9-20.4) and for membership on advisory boards (OR, 6.9; 95% CI, 5.1-9.6). There was a strong relationship between research collaboration and accumulation of industry ties. For 1 additional tie the OR was 2.2 (95% CI, 1.2-3.8) and rose to 6.3 (95% CI, 3.5-11.1) with 3 ties and 41.8 (95% CI, 14.5-143.4) with 6 or more ties. Conclusions: Medical specialists who have research relationships with the pharmaceutical industry are much more likely to have multiple additional ties than those who do not have research relationships. Institutional review should discourage clinical researchers from developing multiple ties.]]> Sat 24 Mar 2018 08:27:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13913 C) and rs5275 (T > C) polymorphisms was performed by real-time polymerase chain reaction using allele-specific probes. Results: Ingestion of any NSAID in the week prior to interview was associated with an elevated risk for ACS: adjusted odds ratio 1.8 (1.2, 2.5). The rs 20417 and rs 5275 polymorphisms were not singly associated with risk for ACS: adjusted odds ratios 1.1 (0.80, 1.5) and 1.2 (0.88, 1.5), respectively. Individually, the polymorphisms did not modify the risk of ACS with the drugs. When analyses were conducted by haplotype, the adjusted odds ratio with celecoxib or rofecoxib in individuals who had one or two copies of the ‘low risk’ haplotype (no GT) was 1.2 (0.29, 5.0), compared with 2.1 (1.1, 4.0) with the ‘high risk’ haplotype (one or two copies of GT). Conclusions: We found little evidence of a gene/drug interaction. We found a statistically non-significant trend toward a lower risk of coronary events with NSAIDs in the presence of the ‘low risk’ haplotype. Even if confirmed, the clinical utility of the finding would be limited as this haplotype is carried by a minority of the population.]]> Sat 24 Mar 2018 08:25:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10038 Sat 24 Mar 2018 08:12:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10462 Sat 24 Mar 2018 08:09:11 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16491 Sat 24 Mar 2018 08:05:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5441 Sat 24 Mar 2018 07:48:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5653 Sat 24 Mar 2018 07:44:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:138 Sat 24 Mar 2018 07:43:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:389 Sat 24 Mar 2018 07:42:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:3600 Sat 24 Mar 2018 07:21:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4758 Sat 24 Mar 2018 07:21:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10522 Mon 23 Sep 2019 11:09:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43405 Fri 16 Sep 2022 10:26:37 AEST ]]>